Merck KGaA Lung-Cancer Drug Misses Trial’s Survival Goal

Merck KGaA’s experimental drug L-BLP25 missed the main goal of a trial in lung cancer patients, denting the company’s ambitions of turning the medicine into a $1 billion-a-year product.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.